Grifols' (GRFS) anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19
Go back to Grifols' (GRFS) anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19| Grifols Sa Barcelona Sponsored ADR (AMEX: GIKLY) | Delayed: 4.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.40 | 52 Week High | $24.05 | |||
| Open | $4.40 | 52 Week Low | $9.74 | |||
| Day High | $4.40 | P/E | N/A | |||
| Day Low | $4.40 | EPS | $0.00 | |||
| Volume | 3 | |||||
| EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) | Delayed: 9.51 +0.09 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.42 | 52 Week High | $21.75 | |||
| Open | $9.51 | 52 Week Low | $6.41 | |||
| Day High | $9.51 | P/E | N/A | |||
| Day Low | $9.51 | EPS | $0.00 | |||
| Volume | 222 | |||||
| GRIFOLS SP ADR-B (NASDAQ: GRFS) | Delayed: 6.48 +0.18 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.30 | 52 Week High | $35.35 | |||
| Open | $6.49 | 52 Week Low | $14.07 | |||
| Day High | $6.66 | P/E | N/A | |||
| Day Low | $6.43 | EPS | $0.00 | |||
| Volume | 3,409,923 | |||||
